Bone Therapeutics to participate in upcoming conferences
Search jobs
Bone Therapeutics to participate in upcoming conferences
Gosselies, Belgium, 20 May 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that its management will provide contributions to the following scientific, business and investor conferences in Q2 2021 and on the following ranges of topics:
• International Society for Cell & Gene Therapy (ISCT) Annual Meeting (26-28 May 2021): Anthony Ting, PhD, Chief Scientific Officer, will give two presentations titled:
- Industry-sponsored cell therapy trials for COVID-19 induced ARDS – An update
- Naming Cell & Gene Therapies: Harmonizing with INN Nomenclature and Regulatory Impacts – Industry Perspective
Bone Therapeutics announces 2020 full year results
Search jobs
Bone Therapeutics announces 2020 full year results
Multiple new collaborations and partnerships to enhance development, manufacturing and commercialization capabilities
Product portfolio broadening from orthopedics into inflammatory conditions, leveraging Bone Therapeutics’ allogeneic MSC platform
Three successful funding operations, licensing agreement and optimization of manufacturing assets
Gosselies, Belgium, 29 April 2021 – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update and full year financial results for the year ending 31 December 2020, prepared in accordance with IFRS as adopted by the European Union.
An Experienced CRO And Sites Lead To Patient Recruitment Success
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
Bone Therapeutics is a public biotech headquartered in Gosselies, Belgium. The company has 35 employees and was founded about 10 years ago. The company has a unique approach to the development of cell therapy products for orthopedics and bone diseases which uses differentiated bone-forming cells.
“We are targeting orthopedic disease and other unmet medical needs primarily with MSCs (mesenchymal stromal cells),” says Miguel Forte, CEO of Bone Therapeutics. “MSCs have multiple functions in controlling disease and regenerating tissues. They are present in several tissues, including bone marrow.”
Hits: 668
Topline results anticipated in H2 2022
GOSSELIES, Belgium I January 12, 2020 I BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has treated the first patient for the ALLOB Phase IIb clinical study in patients with difficult-to-heal tibial fractures.
The ALLOB Tibial Fracture Phase IIb study is a randomized, double-blind, placebo-controlled study. In this study the potential of ALLOB to accelerate fracture healing and prevent late-stage complications in patients with difficult fractures in the shinbone (tibia), will be evaluated and compared to placebo, on top of standard of care after a follow-up period of 6 months. ALLOB will be applied by a single percutaneous injection 24-96 hours post reduction surgery in patients with fresh tibial fractures at risk for delayed or non-union. The study has been approved in 7 European countries (Belgium, Czech Republ
Bone Therapeutics treats first patients in ALLOB Phase IIb tibial fracture study
Topline results anticipated in H2 2022
Gosselies, Belgium, January 12, 2020 – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has it has treated the first patient for the ALLOB Phase IIb clinical study in patients with difficult-to-heal tibial fractures.
The ALLOB Tibial Fracture Phase IIb study is a randomized, double-blind, placebo-controlled study. In this study the potential of ALLOB to accelerate fracture healing, and prevent late-stage complications in patients with difficult fractures in the shinbone (tibia), will be evaluated and compared to placebo, on top of standard of care after a follow-up period of 6 months. ALLOB will be applied by a single percutaneous injection 24-96 hours post reduction surgery in patients with fresh tibial fractures at risk for delay